Cellular compositions and uses thereof
A tendon cell composition expressing TNMD and Scx markers addresses the limitations of existing tendon repair methods by reducing scarring and adhesion, enhancing healing and mobility.
Patent Information
- Application Number
- JP2024534322
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-06
- Filing Date
- 2022-12-02
- Publication Date
- 2024-12-05
AI Technical Summary
Existing methods for tendon repair, such as tenon cell therapy, have poor clinical results due to issues like fibroblast formation, scarring, and adhesion formation, leading to limited tendon mobility and increased pain.
A cell composition comprising isolated tenocytes expressing tenomodulin (TNMD) and scleraxis (Scx) markers, cultured under specific conditions, is developed to inhibit fibroblast formation and promote tendon repair.
The cell composition effectively reduces scarring and adhesion formation, improving tendon healing and mobility, as demonstrated by significant improvements in pain and functional scores in clinical trials.
Smart Images

Figure 2024545139000003 
Figure 2024545139000004 
Figure 2024545139000005
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of a method for isolating and expanding tendon cells in vitro. The present invention also relates to a cell composition comprising such tendon cells and its use for repairing tendon tissue. [Background technology]
[0002] Tendons are a type of regularly arranged dense, soft connective tissue that bridges and attaches muscles to bones. Tendons are composed of type I collagen (80% by weight) arranged in the form of fibrils. Covering the tendons is a thin membrane of fascial tissue. Tendons also contain some elastin fibers, a proteoglycan matrix, and proteinaceous fillers between the connective tissue fibers.
[0003] When tendons are damaged by trauma, accumulated wear or surgical intervention, they usually take longer to heal than, for example, bone. Tendons have a poor spontaneous regenerative capacity and complete regeneration is rarely achieved despite intensive remodeling.
[0004] Patients with ruptured tendons experience pain, reduced mobility, reduced lubrication between the articulating and adjacent tissues, and are at increased risk for post-traumatic scarring, adhesions, and pain. In some cases, during the healing process after a tendon is traumatically injured, the body may deposit excessive amounts of fibrous collagen at the site of injury. Peritendinous adhesions also contribute to poor outcomes in patients undergoing tendon surgery.
[0005] After tendon repair surgery, fibroblasts from the surrounding tissue migrate into the wound during the healing process, resulting in the formation of scar tissue. Peacock E K. In: Peacock EK (ed) Wound repair. WB Saunders, Philadelphia, 1984; pp 263-331. Adhesion formation between the tendon and the surrounding tissue reduces the repaired tendon's ability to move normally. This limits postoperative rehabilitation as a result of reduced range of motion and increased inflammatory pain.
[0006] One method for repairing tendons that has been used to date with mixed results is tenocyte therapy. These procedures typically use fibroblasts, amniotic stem cells, bone marrow aspirates, or other tendon-associated cells that are cultured in vitro for a period of time and then, in some cases, re-embedded within a scaffold structure; however, tenocyte culture has many pitfalls that ultimately have led to poor clinical outcomes.
[0007] Thus, there continues to be a need for improved methods and products that are expected to effectively inhibit fibroblast formation, scarring and adhesion formation in treating ruptured and otherwise injured tendons. Products that are expected to effectively inhibit fibroblast formation, scarring and adhesion formation may be useful in treating ruptured and otherwise injured tendons. The present invention describes products that can alleviate some of the problems discussed above. Summary of the Invention
[0008] The present invention provides a cell composition comprising tendon-derived cells isolated from a tendon.
[0009] In one embodiment of the present invention, a cell composition is provided that comprises isolated tenocytes selected in vitro for expression of both tenomodulin (TNMD) and scleraxis (Scx).
[0010] In some embodiments, the cell composition comprises isolated tendon cells selectively expanded in culture, the tendon cells further expressing one or more markers selected from the group consisting of Col1A1, TSP-4, TNC, DCN, FN1, BGN and FMOD, or a combination thereof, and a pharmaceutically acceptable carrier.
[0011] The level of expression of these markers must be greater than zero, i.e., there must be a detectable level of expression. In one embodiment, the cell composition comprises expanded, isolated tenocytes expressing markers at or above 100 copies per μg of cDNA as detected by droplet digital PCR. Preferably, the expression levels of the markers are a minimum of 5000 copies of Scx, 5000 copies of Col1A1, and 1000 copies of TNMD per μg of cDNA as detected by droplet digital PCR.
[0012] In one embodiment of the present invention, a method is provided for obtaining a cell composition comprising tendon cells, said composition comprising at least 70% viable tendon cells, the method comprising the steps of obtaining a sample of a mammalian tendon; obtaining a tendon cell suspension from said tendon by performing at least one enzymatic dissociation step; culturing said cell suspension under suitable conditions; selecting tendon cells that express both tenomodulin (TNMD) and scleraxis (Scx); and proliferating the selected tendon cells under suitable conditions to achieve a therapeutic amount.
[0013] Preferably, the tenocytes are derived from a tendon sample or a tendon biopsy, but the source of tenocytes may also be isolated tendons. Depending on the nature of the tendon sample, the method preferably comprises a separation step, whereby the tenocytes are at least partially separated from the tendon sheath. This separation may be purely mechanical, for example by using forceps, a scalpel or tweezers, or it may involve the use of dissociation agents such as enzymes. In one embodiment, both methods may be combined.
[0014] The dissociated tenocytes are preferably cultured in a growth medium. The growth medium may comprise a conditioned medium or an unconditioned medium. Examples of suitable conditioned medium include Iscove's modified Dulbecco's medium (IMDM), Dulbecco's minimum essential medium (DMEM) or alpha minimum essential medium (MEM) or equivalent media. Examples of suitable unconditioned medium include IMDM, DMEM or alphaMEM or equivalent media. The medium may be supplemented with serum (e.g. bovine serum, fetal bovine serum, calf serum, horse serum, human serum or artificial serum substitutes [e.g. 1% bovine serum albumin, 10 μg / ml bovine pancreatic insulin, 200 μg / ml human transferrin, 10 -4 M β-mercaptoethanol, 2 mM L-glutamine and 40 μg / ml LDL (low density lipoprotein)]) or may be serum-free.
[0015] In one embodiment, the growth medium comprises 20% v / v fetal bovine serum (FBS) in DMEM™ F12 supplemented with ascorbic acid (0.017 mg / mL).
[0016] After the tendon cells reach a desired level of proliferation, the tendon cells are harvested and formed into a cell composition in a therapeutic amount to prevent or treat tendon injury. In one embodiment, the proliferated tendon cells are harvested by centrifugation and added to a suitable pharma- ceutical acceptable carrier in a therapeutic amount, typically 1-10×10 6 The tenocytes are resuspended in 100 ml of 10 ... [Brief description of the drawings]
[0017] [Figure 1]Figure 1 shows total gene expression across culture conditions. Gene expression data was analyzed in various culture conditions: A, minimal handling; B, half medium change on day 3; C, with 5% serum supplementation; D, starved medium; and E, passage at subconfluence. [Diagram 2] Figure 2 shows the expression (copies / μg cDNA) distribution plot of scleraxis (Scx) in PD tenocytes. [Diagram 3] Figure 3 shows collagen I (Col1A1) expression (copies / μg cDNA) distribution plot of PD tenocytes. [Figure 4] Figure 4 shows a distribution plot of tenomodulin (TNMD) expression (copies / μg cDNA) in PD tendon cells. [Diagram 5] FIG. 5 shows the mean ASES scores at baseline and at 1, 3, 6 and 12 months after treatment with cellular composition (ATI) or corticosteroids (CS). Error bars = standard error of the mean. Dotted lines indicate that there was significant dropout in the corticosteroid group at 12 months (n=4). p values provide statistically significant differences between groups. NS = no statistically significant differences between groups. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Detailed Description of the Invention In accordance with the present invention, conventional molecular biology, microbiology, cell biology, cell culture, and recombinant DNA techniques may be employed within the skill of the art. Such techniques are fully explained in the literature. See, for example, Sambrook, Fritsch, & Maniatis; DNA Cloning: A Practical Approach, Volumes I and II (DN Glover ed. 1985); Oligonucleotide Synthesis (MJ Gait ed. 1984); Nucleic Acid Hybridization BD Hames & SJ Higgins eds. (1985); Transcription and Translation BD Hames & SJ Higgins eds (1984); Animal Cell Culture RI Freshney, ed. (1986); Immunobilized Cells and enzymes IRL Press, (1986), and B. Perbal, A Practical Guide to Molecular Cloning (1984). The present invention may also employ standard methods in immunology known in the art.
[0019] Unless otherwise specified, all terms used in the disclosure of the present invention, including technical and scientific terms, have the meanings as commonly understood by one of ordinary skill in the art to which the present invention belongs. By way of further guidance, definitions of terms are included to better understand the teachings of the present invention.
[0020] The following terms, as used herein, have the following meanings: It is noted that references herein to "embodiments," "some embodiments," "other embodiments," and the like, indicate that the described embodiment may include a particular feature, structure, or characteristic, but not all embodiments may necessarily include that particular feature, structure, or characteristic. Moreover, such phrases do not necessarily refer to the same embodiment. Moreover, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is believed to be within the knowledge of one of ordinary skill in the art to affect such feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless expressly stated otherwise. That is, it is contemplated that the various individual elements described below, even if not explicitly shown in a particular combination, can be combined or arranged with one another to form other additional embodiments and to complement and / or enhance the described embodiments, as would be understood by one of ordinary skill in the art.
[0021] The recitation of numerical ranges by limits includes the stated limits, as well as all numbers and fractions subsumed within the range.
[0022] The expression "wt. %" (weight percent) throughout this specification, unless otherwise specified, refers to the relative weight of each component based on the total weight of the formulation.
[0023] The expression "v / v%" (volume percent) throughout this specification, unless otherwise specified, refers to the relative volume of each component based on the total volume of the formulation.
[0024] "A" and "the" are used herein to refer to singular and plural referents unless the context clearly dictates otherwise. As an example, "a cell" refers to one or more than one cell.
[0025] As used herein, "about," when modifying a measurable value, such as a parameter, amount, temporal duration, is meant to encompass a variation of no more than ±20%, preferably no more than ±10%, more preferably no more than ±5%, even more preferably no more than ±1%, and even more preferably no more than ±0.1% of the indicated value, provided such variation is appropriate for performance in the disclosed invention, but it is understood that the value to which the modifier "about" refers is itself specifically disclosed.
[0026] The terms "comprise," "comprising," and "comprises," as well as "composed of," are used herein synonymous with "include," "including," "includes," or "contain," "containing," or "contains," and are inclusive or open-ended terms that specify the presence of what follows, such as components, and do not exclude or preclude the presence of additional, unrecited components, features, elements, members, or steps that are known in the art or disclosed therein.
[0027] "Tissue" refers to an aggregate of cells having similar morphology and function.
[0028] "Tendon" means the dense fibrous connective tissue found in mammals and is composed primarily of collagen fibers contained within the tendon sheath.
[0029] "Tendon sample" means a fragment, section or biopsy of tendon, said sample comprising bundles of fibres containing tendon cells.
[0030] The term "tendon cells" as used herein encompasses cells isolated from or derived from tendons, including cells cultured in vitro.
[0031] "Proliferation" means an increase in tendon cell number.
[0032] "Dissociating a tendon sample" means separating tendon tissue into single tendon cells, small cell clusters or smaller pieces of tissue.
[0033] The term "enzymatic dissociation process" is to be understood as any process involving an enzyme or a solution containing an enzyme (digestion solution) that results in the complete or partial cleavage of the cellular connections that are normally present in a geometrically arranged two- or three-dimensional structure, e.g. a sample of tendon. As a final result, a tenocyte solution is finally obtained that preferably consists mainly of single tenocytes and / or tenocyte clusters. Dissociation preferably occurs by disrupting the adhesion bonds between the cells of the tenocytes.
[0034] Preferably, said enzymatic dissociation step is followed by a mechanical separation of the tendon cells from the tendon sheath. A cell suspension can be obtained after said mechanical separation of the tendon cells from the tendon sheath, preferably by one or more enzymatic dissociation steps.
[0035] In a more preferred embodiment, the enzymatic dissociation step is expected to increase the rate of isolation of tenocytes. Suitable enzymatic solutions (digestion solutions) that can be used for this enzymatic dissociation step may include collagenase type I, collagenase type II, collagenase type III, papain and dispase. Preferably, the enzymatic dissociation step includes collagenase type II.
[0036] Preferably, the cells will be plated in a growth medium (tendon cell medium) specifically optimized for the culture and growth of tendon cells. In an embodiment of the present invention, the growth medium may comprise a conditioned medium or an unconditioned medium. Examples of suitable conditioned medium include IMDM, DMEM or αMEM or equivalent media. Examples of suitable unconditioned medium include Iscove's Modified Dulbecco's Medium (IMDM), DMEM or αMEM or equivalent media. The medium may be supplemented with serum (e.g. bovine serum, fetal bovine serum, calf serum, horse serum, human serum or artificial serum substitutes [e.g. 1% bovine serum albumin, 10 μg / ml bovine pancreatic insulin, 200 μg / ml human transferrin, 10 -4 The medium may contain serum (0.1 mM β-mercaptoethanol, 2 mM L-glutamine and 40 μg / ml LDL (low density lipoprotein)] or may be serum-free.
[0037] In one embodiment, the growth medium comprises 20% v / v fetal bovine serum (FBS) in DMEM™ F12 supplemented with ascorbic acid (0.017 mg / mL).
[0038] Typically, the resulting population of tenocytes will comprise at least 70% tenocytes. More preferably, the resulting cell population will comprise at least 80% tenocytes, even more preferably at least 90% tenocytes. In the most preferred embodiment, the resulting cell population will consist of 100% pure tenocytes.
[0039] To ensure that a truly pure cell composition has been obtained, the obtained tenocytes are tested by the use of suitable markers. In an embodiment of the invention, the cell composition comprises tenocytes expressing the molecular markers TNMD and Scx, as defined herein. Preferably, the tenocytes further express one or more of the markers Col1A1, TSP-4, TSC, DCN, FN1, BGN and FMOD.
[0040] In the most preferred embodiment, a combination of markers is tested to obtain a final result. This makes it possible to distinguish the nature of the isolated and purified tenocytes and to establish the purity of the obtained sample. Cells that do not comply with the presence of the above-mentioned markers are not considered as tenocytes useful in tendon repair. The method according to the invention allows to obtain very high yields of pure tenocyte populations (up to 100%). This is of great importance for any downstream applications.
[0041] In some embodiments, the tenocytes of the invention have minimal expression of the expression markers. In a preferred example, the expression markers are expressed as copy number per μg of cDNA as measured by droplet digital PCR (ddPCR). Prior to using autologous cells for transplantation, ddPCR is used as part of a series of analyses to evaluate the purity, potency and identity (PPI) of the cells. ddPCR measures the expression of key phenotype-specific marker genes, which are expected to remain within certain levels for approval of use of the cultured cells.
[0042] The level of expression of the markers must be greater than zero, i.e., there must be a detectable level of expression. In one embodiment, the cell composition comprises expanded isolated tenocytes expressing markers at or above 100 copies per μg of cDNA as detected by droplet digital PCR. Preferably, the minimum expression levels of the markers are as follows: Scx 5000 copies, Col1A1 5000 copies, and TNMD 1000 copies per μg of cDNA as detected by droplet digital PCR. In some embodiments, the minimum expression of Scx and Col1A1 is 10,000 copies per μg of cDNA.
[0043] "Cell viability" refers to cell survival rate.
[0044] "Reducing cell death" means reducing the predicted tendency or probability that a cell will die. Cell death may be by apoptosis, necrosis, or other means.
[0045] "Cellular factor" refers to any biological substance produced by a cell. Cellular factors isolated from the medium are typically secreted by cells during culture, but the scope of the present invention is intended to include any factor released into the growth medium by cultured cells. In one embodiment, the cellular factors of the present invention are secreted by the cells or released into the medium when the cells break down and release their contents into the growth medium. Exemplary cellular factors include HGF, VEGF, SDF-1α, and IGF-1.
[0046] "Secreted cellular factor" means any biologically active substance secreted by cells during in vitro culture.
[0047] "Agent" means any small molecule chemical compound, antibody, nucleic acid molecule or polypeptide, or fragments thereof.
[0048] "Ameliorate" means to decrease, inhibit, attenuate, reduce, halt or stabilize the development or progression of a disease.
[0049] "Alteration" refers to a change (increase or decrease) in expression levels or activity of a gene or polypeptide as detected by standard art-known methods, such as those described herein. As used herein, alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50% or greater change in expression levels.
[0050] "Derived" as used herein refers to the process of obtaining tendon cells from a subject, tendon sample or cell culture.
[0051] "Detect" refers to determining the presence, absence, or amount of the object being detected.
[0052] "Detectable label" refers to a composition that, when attached to a molecule of interest, renders the molecule detectable via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (e.g., those commonly used in ELISA), biotin, digoxigenin, or haptens.
[0053] "Disease" means any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include any disease or injury involving tissue damage or injury that results in a reduction in cell number or biological function.
[0054] As used herein, the terms "prevent," "preventing," "prevention," "prophylactic treatment," and the like refer to reducing the likelihood of a disorder or condition occurring in a subject who does not have the disorder or condition but is at risk of or susceptible to developing it.
[0055] "Repair" means ameliorating damage or disease in a tissue or organ.
[0056] As used herein, the terms "treat," "treating," "treatment," and the like refer to reducing or ameliorating a disorder and / or symptoms associated therewith. It will be understood that treating a disorder or condition does not require, although not excluded, that the disorder, condition, or symptoms associated therewith be completely eliminated.
[0057] By "marker" or "expression marker" is meant any protein or polynucleotide having an alteration in expression level or activity associated with culturing the tendon cells or tendon-derived cells of the invention in vitro. Markers of the invention include scleraxis (Scx), collagen I (Col1A1), tenomodulin (TNMD), thrombospondin-4 (TSP-4), tenascin-C (TNC), decorin (DCN), fibronectin (FN1), biglycan (BGN) and fibromodulin (FMOD). Many of these markers have multiple isoforms, and the term marker as used herein includes all isoforms.
[0058] As used herein, "obtaining" includes synthesizing, purchasing, or otherwise acquiring an agent, for example in "obtaining an agent."
[0059] "Reference" means a standard or control condition.
[0060] A "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, a full-length cDNA or gene sequence, or a segment of a full-length cDNA or gene sequence. For polypeptides, the length of a reference polypeptide sequence is generally expected to be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of a reference nucleic acid sequence is generally expected to be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, even more preferably about 100 nucleotides, or about 300 nucleotides, or any integer number therebetween.
[0061] "Substantially identical" refers to a polypeptide or nucleic acid molecule that exhibits at least 50% identity to a reference amino acid sequence (e.g., any of the amino acid sequences described herein) or nucleic acid sequence (e.g., any of the nucleic acid sequences described herein). Preferably, such a sequence is at least 60%, more preferably 80% or 85%, more preferably 90%, 95% or even 99% identical at the amino acid or nucleic acid level to the sequence used for comparison.
[0062] Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; phenylalanine, tyrosine. An exemplary approach for determining the degree of identity may use the BLAST program, e.g., BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX. -3 ~e -100 A probability score of 0.05 indicates closely related sequences.
[0063] "Patient" refers to an animal, preferably a human, to whom treatment, including prophylactic treatment, with the cells, preparations and compositions of the present invention is provided. When treating a condition or pathology specific to a particular animal, such as a human patient, the term refers to that particular animal. "Donor" refers to an individual (animal, including a human) who provides tendon cells for use in a patient. In many cases, it is anticipated that the donor will also be a patient, i.e., autologous treatment.
[0064] "Effective amount" refers to a concentration of a component, such as a growth factor, cell, preparation or composition, effective to produce an intended result, including proliferation of tendon cells, or to effect transplantation of cells into a patient for whom a disease or condition is being treated or sought to be treated with the cells, preparations and cell compositions of the present invention.
[0065] "Therapeutic amount" refers to the volume or number of expanded tendon cells in the cell composition of the present invention that can prevent or treat tendon injury. The volume or number of tendon cells depends on the patient and the nature of the injury. One example is 1×10 6 in the range of cells / 1 ml; however, the exact amount or volume will depend on clinical factors.
[0066] The term "administering" or "administration" refers to the method of delivering the cells, preparations or compositions of the invention to a patient for treatment purposes: the cells, preparations or compositions may be administered in a number of ways, including parenterally (e.g., intravenously and intraarterially, other suitable parenteral routes), orally, subcutaneously, by inhalation or transdermally. The cells, preparations and compositions of the invention are administered in accordance with good medical practice, taking into account the clinical condition of the patient, the site and method of administration, dosage, the age, sex, weight of the patient, and other factors known to the physician.
[0067] "Transplanting," "transplantation," "grafting," and "graft" are used to describe methods of delivering the cells, preparations, and compositions of the invention to a site within a patient where the cells are intended to exert a beneficial effect, such as repairing damage to a patient's tissue, treating disease, injury or trauma, genetic damage, or environmental damage to an organ or tissue caused, for example, by an accident or other activity. The cells, preparations, and compositions may be delivered to remote areas of the body by any mode of administration that relies on migration of cells to the appropriate area within the body to achieve implantation.
[0068] "Essentially" refers to a population of cells or a method that is at least 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more or 95% or more effective, more preferably at least 98% or more effective, and most preferably 99% or more effective. Thus, a method of enriching a given cell population will enrich the cell population of interest by at least about 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80%, 85%, 90% or 95%, most preferably enriching the cell population by at least about 98%, and most preferably enriching the cell population by about 99%. In certain embodiments, the cells in the enriched tendon or tendon cell population of the invention essentially comprise cells that express the markers Scx and TNMD, and preferably also express one or more of the markers Col1A1, TSP-4, TSC, DCN, FN1, BGN, FMOD, or a combination thereof.
[0069] "Isolated" or "purified" refers to alteration "by the hand of man" from the native state, i.e., something found in nature is defined as isolated if it is removed from its original environment. In one embodiment, a population or composition of cells is substantially free of cells and materials with which it may be associated in nature. By substantially free or substantially purified, it is meant that at least 50% of the population are target cells, preferably at least 70%, more preferably at least 80%, and even more preferably at least 90% are free of other cells. The purity of a population or composition of cells can be assessed by suitable methods well known in the art.
[0070] "Fragment" refers to a portion of a polypeptide or nucleic acid molecule. The portion preferably contains at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the full length of the nucleic acid molecule or polypeptide. A fragment may have 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
[0071] An "isolated polynucleotide" refers to a nucleic acid (e.g., DNA) that is free of genes that flank it in the naturally occurring genome of the organism from which the nucleic acid molecule of the invention is derived. Thus, the term includes, for example, recombinant DNA incorporated into a vector, an autonomously replicating plasmid or virus; recombinant DNA incorporated into the genomic DNA of a prokaryote or eukaryote; or recombinant DNA that exists as a separate molecule independent of other sequences (e.g., cDNA or genomic or cDNA fragments produced by PCR or restriction endonuclease digestion). In addition, the term includes RNA molecules transcribed from a DNA molecule, and recombinant DNA that is part of a hybrid gene that encodes another polypeptide sequence.
[0072] method The present invention relates to a method for obtaining a cell composition comprising tenocytes isolated from a mammalian tendon, said composition comprising at least 70% viable tenocytes, which compositions can be used for various tendon repair needs due to their proliferative nature.
[0073] The method according to the invention can be carried out on tendon tissue of any type and origin. Preferably, mammalian tendons are expected to be the basis of the obtained cell composition. Said mammalian tendons can be obtained, for example, but not limited to, from humans, mice, dogs, cats, sheep, cows, pigs, horses, rabbits, rats, guinea pigs, other rodents, etc.
[0074] In one preferred embodiment, the tenocytes are isolated and purified from the human subject to be treated, i.e. the tenocytes are autologous tenocytes.
[0075] Tendon cell isolation In one embodiment, a tendon sample is obtained by standard biopsy from a subject or patient. The tendon is mechanically and / or chemically dissociated and filtered through a sieve or strainer to produce individual tenocytes. The tenocytes are then washed, counted, and resuspended in growth medium using standard tissue culture techniques.
[0076] Media and reagents for tissue culture are well known in the art (see, e.g., Pollard, JW and Walker, JM (1997) Basic Cell Culture Protocols, Second Edition, Humana Press, Totowa, NJ; Freshney, RI (2000) Culture of Animal Cells, Fourth Edition, Wiley-Liss, Hoboken, NJ). Examples of media suitable for incubating tendon cells include, but are not limited to, Dulbecco's Modified Eagle Medium (DMEM), RPMI medium, Hank's Balanced Salt Solution (HBSS), phosphate buffered saline (PBS), and other media known in the art. Examples of suitable media for culturing the cells of the present invention include, but are not limited to, Dulbecco's Modified Eagle Medium (DMEM), RPMI medium. The media may be supplemented with fetal calf serum (FCS) or fetal bovine serum (FBS), as well as antibiotics, growth factors, amino acids, inhibitors, and the like, which are well within the general knowledge of the skilled artisan.
[0077] In some embodiments, the growth medium may comprise a conditioned medium or an unconditioned medium. Examples of suitable conditioned medium include IMDM, DMEM, or αMEM, or an equivalent medium. Examples of suitable unconditioned medium include Iscove's Modified Dulbecco's Medium (IMDM), DMEM, or αMEM, or an equivalent medium. The medium may be supplemented with serum (e.g., bovine serum, fetal bovine serum, calf serum, horse serum, human serum, or artificial serum substitutes [e.g., 1% bovine serum albumin, 10 μg / ml bovine pancreatic insulin, 200 μg / ml human transferrin, 10 -4The medium may contain serum (0.1 mM β-mercaptoethanol, 2 mM L-glutamine and 40 μg / ml LDL (low density lipoprotein)] or may be serum-free.
[0078] In one embodiment, the growth medium comprises 20% v / v fetal bovine serum (FBS) in DMEM™ F12 supplemented with ascorbic acid (0.017 mg / mL).
[0079] Once the tenocytes are resuspended in growth medium, they are cultured for a period of time to increase their number. Growth conditions require culturing the enriched explant tenocyte preparation for a period of time sufficient to increase the number of explant tenocytes in the preparation while maintaining expression of specific markers. The cells are typically maintained so that the cells complete about 1-100 cell cycles, preferably 5-75 cell cycles; more preferably 2-50, 2-40 or 2-20 cell cycles, and most preferably at least about 2-10 or 4-5 cell cycles. This typically corresponds to a culture period of about 4-40 days, preferably a culture period of about 2-20 days, more preferably a culture period of at least or about 2-15 days or 4-10 days, and most preferably a culture period of at least or about 4-8 days.
[0080] The frequency of feeding the enriched explant tenocyte preparation is selected to promote survival and proliferation of cells with or increased ability to express the desired cell markers. In one embodiment, the cells are fed once or twice a week. The cells may be fed by replacing the entire medium with fresh medium, or preferably a predetermined percentage of the medium, so that cellular factors released by the explant cells are not lost.
[0081] In a preferred embodiment, a "half medium" nutrient supply is used. Without wishing to be limited by theory or hypothesis, the purpose of the half medium nutrient supply is to utilize the secretome (conditioned medium) of tendon cells. In this specification, the term secretome includes proteins shed from the surface of tendon cells, as well as intracellular proteins released by non-classical secretory pathways or exosomes during in vitro culture. These secreted proteins include various enzymes, growth factors, cytokines and hormones, or other soluble mediators. Cells other than tenocytes in culture have been reported to secrete proteins that may affect cell proliferation, differentiation, invasion and angiogenesis by modulating cell-cell and cell-extracellular matrix interactions (see Dowling & Clynes, 2011, Proteomics 2011, 11, 794-804).
[0082] As with many standard cell culture methods, the tenocytes of the present invention require regular passaging. In one embodiment of the present invention, passaging comprises a trypsinization step, which is carried out under conditions that allow the release of the tenocytes from the tendon structure. Trypsinization can be carried out at room temperature (20-25°C) or at lower or higher temperatures (e.g. 37 or 38°C) for a period of time long enough to disrupt the connections between the cells.
[0083] The methods of the invention can be carried out on a large scale, for example, cell compositions of the invention can be isolated and / or grown in bioreactors.
[0084] The methods of the present invention result in a newly created cell composition comprising a population of explant tendon cells that have the capacity, or an increased capacity, to repair tendons in vivo.
[0085] In one aspect of the invention, an isolated and purified cell composition is provided that comprises, or essentially comprises, tenocytes characterized by expression of the markers tenomodulin (TNMD) and scleraxis (Scx).
[0086] In some embodiments, the purified cell composition comprises isolated tendon cells selectively expanded in culture, which tendon cells further express one or more markers selected from the group consisting of Col1A1, TSP-4, TSC, DCN, FN1, BGN and FMOD, or a combination thereof.
[0087] The level of expression of the markers must be greater than zero, i.e., there must be a detectable level of expression. In one embodiment, the cell composition comprises expanded isolated tendon cells expressing markers at or above 100 copies per μg of cDNA as detected by droplet digital PCR. Preferably, the expression levels of the markers are a minimum of 5,000 copies of Scx, 5,000 copies of Col1A1, and 1,000 copies of TNMD per μg of cDNA as detected by droplet digital PCR. In some embodiments, the minimum expression of Scx and Col1A1 is 10,000 copies per μg of cDNA.
[0088] The techniques for ddPCR are well known and understood by those skilled in the art. In a preferred embodiment, ddPCR is performed using a Bio-Rad QX200™ ddPCR system that utilizes microfluidics technology to partition the ddPCR reaction into nanoliter droplets (20,000 water-in-oil emulsion droplets for the QX200 system) in which individual ddPCR reactions are performed. Since the sample is partitioned into single droplets (volume of about 1 nL), it is considered that an independent PCR reaction is performed in each droplet during amplification. Amplification is performed for 40 cycles, and after completion, the fluorescence of the sample is quantified using a digital reader that establishes an amplification threshold. Poisson statistics are then applied to the ratio of positive droplets to total droplets to determine the absolute concentration of the target in copies per microliter (cp / μL) in the ddPCR reaction.
[0089] All oligonucleotides (primers, probes and minigenes) used in ddPCR may be custom designed and manufactured, for example, by Integrated DNA Technologies (IDT). Upon receipt, fluorescent probes are diluted to 100 μM in TE buffer, pH 8.0, and stored at -20°C, avoiding exposure to ambient light, to maintain maximum performance, stability and shelf life. Primers are typically shipped "lab-ready" at a stock concentration of 100 μM in TE buffer, pH 8.0, and are stored at -20°C upon receipt. Working stocks of all oligonucleotide products are prepared in TE buffer, pH 8.0, at the concentrations recommended for ddPCR (i.e., 5 μM for probes and 25 μM for primers).
[0090] ddPCR assay controls are included to confirm the integrity of the assay including RNA extraction, cDNA synthesis, ddPCR negative controls are included to ensure the absence of extraneous RNA or reagent contamination, elimination of self-amplification (e.g., due to primer dimers), as well as a reverse transcriptase control and a positive control (minigene).
[0091] The cell compositions of the present invention can also be prepared using positive or negative selection techniques other than expression markers, based on one or more of the characteristics of the cells of the composition described herein.
[0092] Cellular modification The cell preparation or cell composition of the invention may be derived from or consist of tendon cells that have been genetically modified (transduced or transfected) either naturally or by genetic engineering techniques in vivo or in vitro.
[0093] The cells in the cell preparations and compositions of the invention may be modified by introducing mutations into genes in the cells (or the cells from which they are derived) or by introducing transgenes into the cells. Insertion or deletion mutations can be introduced into the cells using standard techniques. Transgenes can be introduced into the cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran mediated transfection, lipofection, electroporation or microinjection. Suitable methods for transforming and transfecting cells can be found in Sambrook et al., and other laboratory textbooks. By way of example, transgenes can be introduced into the cells using appropriate expression vectors, examples of such vectors include, but are not limited to, cosmids, plasmids or modified viruses (e.g., replication-deficient reoviruses, adenoviruses and adeno-associated viruses). Transfection can be easily and efficiently obtained using standard methods, including culturing the cells on a monolayer of virus-producing cells.
[0094] A gene encoding a selectable marker may be incorporated into the cells of the cell preparation or composition of the present invention. For example, a gene encoding a protein such as β-galactosidase, chloramphenicol acetyltransferase, firefly luciferase or a fluorescent protein marker may be incorporated into the cells. An example of a fluorescent protein marker is the green fluorescent protein (GFP) from the jellyfish A. victoria or a variant thereof that retains its fluorescent properties when expressed in invertebrate cells.
[0095] Another aspect of the invention relates to genetically engineering the cells in the cell preparations and compositions of the invention in such a way that the cells in the cell preparations and compositions of the invention or cells derived therefrom produce in vitro or in vivo polypeptides, hormones and proteins that are not normally produced in biologically significant amounts in the cells or are produced in low amounts, but in situations where regulated expression is believed to provide therapeutic benefit. For example, the cells can be modified to express even lower levels of normally expressed proteins. These products are then expected to be secreted or purified from the cells into the surrounding medium. The cells thus formed may serve as continuous short-term or long-term production systems for the expressed substances.
[0096] Thus, genes can be introduced into cells and such cells are then injected into a recipient where expression of the gene has a therapeutic effect.
[0097] Other procedures that can be used for the selection of the desired tendon cells include, but are not limited to, density gradient centrifugation, flow cytometry, magnetic separation with antibody-coated magnetic beads, affinity chromatography, cytotoxic substances such as, but not limited to, complement and cytotoxins conjugated to or used in combination with mAbs, panning with antibodies bound to solid matrices, or any other convenient technique. Cells can be selected for dead cells by employing a dye that associates with dead cells, such as propidium iodide (PI). Preferably, cells are harvested in a medium containing (αMEM), fetal calf serum (FCS) or bovine serum albumin (BSA), or any other suitable, preferably sterile, isotonic medium. The selected cells of the present invention can be employed for the isolation of secreted cellular factors as described herein.
[0098] In one embodiment, the selected cells of the present invention comprise a purified population of tendon cells selected for expression of TNMD and Scx. Preferably, the tendon cells further express one or more markers selected from the group consisting of ColI, TSP-4, TSC, DCN, FN1, BGN and FMOD or a combination thereof. A person skilled in the art can easily determine the percentage of tendon cells in a population using a variety of well-known methods such as fluorescence activated cell sorting (FACS). Preferred ranges of purity in a population comprising selected cells are about 50 to about 55%, about 55 to about 60% and about 65 to about 70%. More preferably, the purity is at least about 70%, 75% or 80% pure, more preferably at least about 85%, 90% or 95% pure. In some embodiments, the population is at least about 95% to about 100% selected cells.
[0099] The selected cells can be grown in culture for hours, days, or even weeks, during which time the medium becomes enriched with one or more secreted cellular factors that support tendon cell proliferation, reduce tendon cell death, preserve tendon function after an injury event, prevent or reduce tendon damage, increase tendon function, increase tendon healing, or increase tendon regeneration. Medium enriched with such biologically active substances is referred to as a "conditioned medium."
[0100] Optionally, the tendon cells or their progeny are cultured under conditions that maintain the cells in a proliferative state. In one embodiment, the cells are immortalized to enhance their proliferation. Methods for immortalizing cells are known in the art, and include, but are not limited to, expressing in the cells one or more of dominant negative p53, telomerase, beta-catenin, notch and / or transcription factors, or other polypeptides that promote proliferation of cells (e.g., proliferation of stem cells). The aforementioned polypeptides may be expressed using any vector (e.g., viral vector) suitable for expression in epicardial progenitor cells.
[0101] cold storage If desired, the expanded tenocytes may be cryopreserved using standard techniques for future use.
[0102] Use and Mode of Administration After the tendon cells have reached a desired level of proliferation, the tendon cells may be harvested and formed into a cell composition in a therapeutic amount to prevent or treat tendon injury. In one embodiment, the proliferated tendon cells are harvested by centrifugation and added to a suitable pharma- ceutical acceptable carrier in a therapeutic amount, typically 1-10 x 10 6 The tenocytes are resuspended in 100 ml of 10 ...
[0103] The tenocyte preparations and compositions of the present invention can be used in a variety of ways (e.g., transplantation) and have numerous applications in the medical field: they can be used to replace tendons, or tendon components or structures, lost or damaged due to trauma, age, metabolic or toxic insults, disease, idiopathic loss, or any other cause.
[0104] Tendons that can be repaired using the cell composition of the present invention include tendons with underlying causes of tendinopathy, tendinitis, tendinosis, tenosynovitis, intraparenchymal tendon rupture, or complete tendon rupture. Examples of tendon rupture include, but are not limited to, Achilles tendon rupture, patellar tendon rupture, or biceps tendon rupture, all of which can be surgically repaired using methods according to embodiments of the present invention. Furthermore, it is envisioned that the cell composition of the present invention can be used to repair ligaments, which are very similar in structure to tendons.
[0105] Transplantation, grafting or administration, as used interchangeably herein, may include isolating a cell preparation according to the invention and transferring the cells in the preparation to a mammal or patient. Transplantation may include transferring the cells to a mammal or patient by injection of a cell suspension into the mammal or patient, surgical implantation of a cell mass into the tissue of the mammal or patient, or perfusion of the tissue or organ with a cell suspension. The route of cell transfer may be determined by the requirement for the cells to reside in a particular tissue and by the ability of the cells to find and be retained by the desired target tissue or organ. The transplanted cells may be surgically placed in the tissue if they are to reside in a particular configuration.
[0106] The present invention can be used in autologous transplants (cells from an individual are used in the same individual), allogeneic transplants (cells from one individual are used in another individual) and xenogeneic transplants (transplants from one species to another). Thus, the cells, cell preparations and cell compositions of the present invention can be used in autologous or allogeneic transplants to improve tendon or tendon cell defects or to repair tissue.
[0107] The present invention also contemplates pharmaceutical compositions comprising the cells, cell preparations or cell compositions of the present invention and pharma- ceutically acceptable carriers, excipients or diluents. The pharmaceutical compositions described herein can be prepared by methods known per se for the preparation of pharma- ceutically acceptable compositions that can be administered to a subject, such that an effective amount of an active substance is combined in a mixture with a pharma- ceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). Based on this, compositions include, but are not limited to, solutions of cells, cell preparations or cell compositions, together with one or more pharma- ceutically acceptable vehicles or diluents, that have a suitable pH and are contained in a buffered solution that is isotonic with physiological fluids.
[0108] Yet another aspect of the invention is a kit for producing the cell composition of the invention comprising cells with or with increased capacity to form tendon tissue in vivo. The kit includes reagents for the method of the invention for producing the cell composition. The kit would preferably include at least one positive growth factor and instructions for use.
[0109] In one general embodiment, the expanded tendon cells are used to seed or anchor a construct, such as a scaffold, for use in surgical repair of tendons. The construct may be rigid, semi-rigid, or flexible. In use, the construct covers the tendon or a portion of the tendon and then adheres to the tendon. The construct may be placed over or preferably wrapped around the tendon after surgical repair of the diseased or damaged tendon during a surgical or clinical procedure. The diseased or damaged tendon may be, for example, the tibial tendon, peroneus brevis, longus tendon, etc. The method may further include treating the subject with one or more additional therapies for the diseased or damaged tendon, such as physical therapy, NSAIDs, etc.
[0110] The present invention is further described by the following non-limiting examples, which further illustrate the present invention and are not intended, nor should they be construed, as limiting the scope of the invention. EXAMPLES
[0111] Example 1 Tendon cell isolation and purification Biopsy tendon tissue is removed from the patient using sterile forceps and / or a sterile scalpel, placed in a sterile Petri dish, and diced or minced using a sterile scalpel. Digest solution (>100U / mL) is added and the Petri dish is placed on an orbital shaker and run at 150 rpm, 37°C for 2-4 hours or until the tendon biopsy is dissociated into individual cells. Digest is then stopped by adding growth medium (20% v / v fetal bovine serum (FBS) in DMEM™ F12 supplemented with ascorbic acid (0.017mg / mL)). Tendon cells (explant tendon cells or explant cells) are then filtered through a 100μm cell strainer, centrifuged using standard procedures, resuspended in 4ml of the above growth medium, and minced to <25cm. 2 Place in a sterile flask.
[0112] The explant cells are then incubated at 37°C, 5% CO2 for 12-24 hours before visual inspection and medium change. Once the explant cells have attached to the flask, they are cultured for 7 days, with either a medium change after 7 days, half a medium change after about 3 days, or trypsinization, depending on the confluency of the cells, as per standard procedures. Passaging of explant cells is usually done on 25 cm plates. 2 , 75cm 2 , 2×175cm 2 Once the explant cells are established, obtain enough explant cells (approximately 10-20 x 10) to allow for the assembly of cryopreservation or treatment samples. 6 Trypsinization is typically performed about every 7 days until a confluency of about 80% is achieved.
[0113] If the cells do not grow well, human serum may be used in the above growth medium. In this case, 5% human serum is supplemented instead of the standard FBS and is only present on the cells for about 3 days. A more common procedure is to change half the medium about every 3 days. The principle of this method is to maintain rather than remove the growth factors produced by the explant cells.
[0114] To prepare the tendon cell treatment samples, the expanded (or previously cryopreserved) explant cells are trypsinized and washed with phosphate-buffered saline (PBS) using standard tissue culture procedures. The expanded tendon cells are then collected by centrifugation and the cell pellet is diluted at 2-5 × 10 in a pharma- ceutically acceptable carrier medium (sometimes referred to as assembly medium) (10% v / v human serum in phenol red-free DMEM™ with ascorbic acid (0.3% v / v; 0.015 mg / mL) and gentamicin (0.1% v / v; 0.05 mg / mL). 6 Resuspend at 100 cells / mL.
[0115] Example 2 Cellular markers in expanded explant tenocytes The explant tenocyte therapy product produced by the method of Example 1 can be used to treat tendon (chronic degenerative tendinopathy) and articular cartilage injuries. Prior to implantation of expanded tenocytes, droplet digital PCR (ddPCR) is used as part of a series of analyses to evaluate the purity, potency and identity (PPI) of the cells. ddPCR measures the expression of key phenotype-specific marker genes, which are expected to be maintained within certain levels for approval of release of cultured cells.
[0116] The ddPCR technique is based on performing a fluorescence-based PCR reaction in thousands of microreaction vessels (droplets) of defined volume (approximately 1 nl) prior to amplification. After amplification, each droplet is analyzed with a fluorescence detector (Bio-Rad QX100 / QX200 droplet reader) and counted as either positive (containing the target) or negative for amplification of the gene of interest. This method allows for direct quantification of the number of target DNA molecules in the reaction, independent of the reaction efficiency.
[0117] Expression thresholds for cultured tendon cells are determined by evaluating the expression levels of genes in primary explant cells after monolayer culture is achieved. As previously explained, applicants have established expected levels of expression based on past data, but some downregulation is expected in association with the transition from in vivo to in vitro growth. It has been noted previously that reevaluation of gene expression data after sufficient accumulation of data is a necessary part of assay development. Thus, data are expressed as reported by Bio-Rad QuantaSoft software based on Poisson statistics, without the use of calibration curves or standards of known concentration. Therefore, in this report, the accumulated data are used to define the minimum copy number of gene expression expected from analysis of cell phenotype.
[0118] The gene copy number (copies / 100 μg RNA) was found to be stably expressed under the culture conditions described in the specification.
[0119] The expression limits were established using a non-parametric approach (percentile values), which is an unbiased evaluation method that is less prone to misinterpretation. This method is based on published guidelines. In this approach, the lower reference limit is established as the value that corresponds to the lower limit of the population X (2.5, 5 or 10) percentile. For example, if a data set consists of 109 data points, the lower reference limit of 2.5% is 0.025 x 109 = 2.725 (rounded to 3). Therefore, for this data set, the third value in the data (sorted in ascending order) represents the lower reference limit or the minimum expression threshold. As a result, a reference range is established based on the majority of the analyzed population.
[0120] The total amount of cDNA per ddPCR reaction (final volume 20 μL) (from Table 1) was used to calculate the copy number of the target gene per μg of cDNA. In this analysis, cultures from all donors processed were evaluated to capture the full range of expression levels expected from inherent biological variability. Historical expression data were then reanalyzed, expressed as copies / μg cDNA, and presented as frequency distribution histograms to visualize the results (Figures 2-4). Collagen I except Acceptable expression levels for all genes were based on the distribution of observed data, with the 5th percentile chosen as the acceptable cutoff point (minimal expression threshold). For collagen 1A1, the cutoff point was chosen as the 10th percentile due to the large distribution in acceptable results. Data evaluated were from samples collected at the start of in vitro culture (PD) to remove the effects of the in vitro culture environment and to accurately represent the gene expression profile of the parental cell population.
[0121] [Table 1]
[0122] To establish a final threshold of expression, the analysis relies on a minimum of 20 PD samples.
[0123] Scleraxis (SCX) The range of SCX expression at the start of in vitro culture is shown in Figure 2 (n=157). SCX expression ranges from 246 to 85,385 copies / μg cDNA (median=7000 copies / μg cDNA) in PD. Because the distribution of results was relatively tight, the 5th percentile result is the lower delimiter of expected expression, using the 8th value (sorted in ascending order) in the data (0.05 x 157 = 7.85) as the cutoff.
[0124] Collagen I (COL1A1) The range of COL1A1 expression at the start of in vitro culture is shown in Figure 3 (n = 157). COL1A1I expression ranged from 0 to 7.69 × 10 in PD. 8 Copies / μg cDNA (median = 2.26 × 10 6 Because the distribution of results was relatively broad, the 10th percentile result was used as the lower delimiter for predicted expression, with the 16th value (sorted in ascending order) in the data (0.1 × 157 = 15.7) used as the cutoff.
[0125] Tenomodulin (TNMD) The range of TNMD expression at the start of in vitro culture is shown in Figure 4 (n=21). TNMD expression ranges from 2082 to 10580 copies / μg cDNA (median=4182 copies / μg cDNA) in PD. Because the distribution of results was relatively small, the 5th percentile result is the lower delimiter of expected expression, and the first value (sorted in ascending order) in the data (0.05 x 21 = 1.05) is used as the cutoff.
[0126] Applicant has evaluated a number of culture samples after the introduction of ddPCR. Cells were analyzed at the beginning of the in vitro culture (Post-digestion / PD sample; time point 1) and at the end of the culture (Before assembly for administration-PA sample; time point 2). The aim of the evaluation at the two time points was to ensure that the expression of specific genes was maintained during the in vitro cell culture. The minimum expression levels described must be achieved after culture at the PA time point. The minimum expression levels are based on historical gene expression data to ensure prediction of the cell phenotype, thus ensuring consistency between manufactured batches.
[0127] Limitations of Expression The minimum expression threshold levels based on the identified percentile values are summarized in Table 2. These values are the minimum expression levels required for cultured cells to be tested prior to assembly of an autologous cell therapy product with phenotype-specific genes. These data indicate that scleraxis can be used as a marker alone (as with collagen I) or both markers can be used together to confirm tendon cell phenotype. When the 10th percentile (lowest 10% of data values) of collagen I expression is plotted, there is a trend towards higher expression of the corresponding scleraxis expression levels. Thus, the observed expression levels are consistent with the prediction that there are more transcription factors targeting a target gene when the expression of the target gene itself is low.
[0128] [Table 2]
[0129] Consideration Analysis of the data regarding copies / μg cDNA is consistent with a full suite of analyses used to determine the cellular characteristics of the cell products, including evaluation of morphology and growth characteristics.
[0130] We established that copy number is the most appropriate method for evaluating ddPCR data and established a minimum expression level (threshold) that defines predictions regarding phenotype-specific gene expression in cultured cells.
[0131] conclusion Analysis of ddPCR data expressed as copies / μg cDNA is more relevant than normalized gene expression ratios of endogenous or housekeeping genes such as GAPDH reported in the literature. Analysis showed that absolute expressions of copies / μg cDNA data are more representative of cellular characteristics with respect to PPIs than relative expressions based on normalized ratios.
[0132] Example 3: A randomized controlled trial of tenocyte transplantation versus corticosteroid injections for rotator cuff tendinopathy and tears. The cell composition of the present invention, comprising autologous tenocytes grown in culture by the method of Example 1 and resuspended in a pharma- ceutically acceptable carrier, i.e., 10% v / v human serum (also referred to as assembly medium) in phenol red-free DMEM™ with ascorbic acid (0.3% v / v; 0.015 mg / mL) and gentamicin (0.1% v / v; 0.05 mg / mL), was characterized by the method of Example 2 and then used in a minimally invasive procedure to address the underlying pathology of rotator cuff tendinopathy and tears. This randomized controlled trial was designed to investigate the feasibility of the tenocytes of the present invention as a new treatment for patients with partial intrastromal rotator cuff tears and tendinopathy. Shoulder function, pain, quality of life, and tendon structure were assessed using validated outcome measures before and 12 months after treatment.
[0133] In this study, 19 participants were randomized to receive treatment with the cell composition of the present invention, and 11 participants were randomized to receive corticosteroid treatment. There were no significant differences in baseline characteristics between the groups, and no participants were lost to follow-up during the 12-month period after treatment. Baseline characteristics confirmed that the two participant groups had chronic degenerative rotator cuff pathology that was unlikely to improve without intervention.
[0134] This study was conducted to provide preliminary evidence of the efficacy, safety, and tolerability of the cell composition of the present invention compared to corticosteroid injections in participants with chronic degenerative rotator cuff tendinopathy with intraparenchymal tendon tears, and to evaluate the feasibility of conducting a large, statistically powered efficacy trial. The data and analyses presented in this report confirm that the study achieved its goals.
[0135] Overall, the two study treatments were well tolerated and no safety concerns were identified with the tenocytes of the present invention. All participants in the cell composition treatment group completed the 12-month follow-up visit, with 64% of the corticosteroid group withdrawing early due to lack of response / treatment failure. Additionally, 54% of the corticosteroid group received additional treatment for their rotator cuff tendinopathy within 12 months of receiving the study treatment.
[0136] Participants treated with the cell composition had statistically and clinically significant improvements in pain and function scores after treatment compared to participants randomly assigned to receive corticosteroid treatment. The improvements in pain and function scores in the cell composition transplant group were clinically meaningful, with the majority of participants reporting scores that reflected a better state. The corticosteroid group experienced a temporary improvement in pain, which peaked at 3 months and then returned to baseline, but no meaningful improvement in function was achieved. MRI scans are useful in the clinic for diagnosing rotator cuff conditions, but are not typically used to monitor the effectiveness of treatment due to the lack of a widely used and validated quantitative method and the known phenomenon that tendon abnormalities observed on MRI do not necessarily indicate the presence of clinically significant symptoms. The results of the analysis of MRI scans are consistent with this, showing a lack of a consistent relationship between tendon structure / tear size and clinical outcome after treatment.
[0137] The results of this study demonstrate that the cell composition of the present invention is more effective than corticosteroid injections in treating rotator cuff tendinopathy with intraparenchymal tendon tears. These data provide evidence supporting key elements of study design, including participant population, sample size calculation, and efficacy endpoints, for a future pivotal randomized controlled trial.
[0138] Briefly, autologous tendon cells were harvested from participants randomly assigned to tenocyte treatment by tendon biopsy under local anesthesia. Using a 14-gauge biopsy needle, a maximum 3 × 1 mm section of tendon was retrieved from the tendon surface. Participants were advised to avoid overuse or excessive repetitive movements for 1–2 days. The patellar tendon was the primary source, but other tendons were selected for biopsy if necessary.
[0139] Approximately 4 weeks after biopsy, up to 2 ml of autologous tenocytes (2–5 × 10 6 Participants were injected with 100 mg of 1000 cells / ml using an 18-gauge needle. Injections were performed at the site of tendon injury / rupture under ultrasound guidance. Participants were advised to rest for 2 days and to limit themselves to light housework / office work for 4 weeks.
[0140] Participants receiving corticosteroid treatment received a single injection of 1 mL of Celestone® Chronodose (betamethasone sodium phosphate 3.9 mg / betamethasone acetate 3 mg) combined with local anesthesia into the subacromial space under ultrasound guidance.
[0141] Efficacy and safety variables Adverse events Information on adverse events was collected from Visit 1 to the final visit. Specific information was collected from participants at each visit via physical examination of affected areas to capture adverse events related to the study treatment or procedure.
[0142] American Society for Shoulder and Elbow Surgery (ASES) The ASES was developed by the American Society for Shoulder and Elbow Surgery to provide a standardized method of evaluating outcomes in multicenter trials of shoulder and elbow surgery. Patients complete a questionnaire that includes items on pain and function, with higher scores indicating worse pain and function. The combined ASES score ranges from 0 to 100, with higher scores indicating better outcomes. A change in ASES score of 12.0 represents the minimal clinically important difference (MCID). Patient acceptable symptom status (PASS) was reported to be 78.6.
[0143] Quality of Life Assessment (AQoL-6D) The AQol-6D is a validated, health-related, multi-attribute, practical measure of quality of life. Patients complete a questionnaire consisting of 20 items across six dimensions (independent living, relationships, mental health, coping behaviors, pain, and sensation). The AQoL can be used for cost-utility analyses and to calculate quality-adjusted life years. Scores range from 0 (death) to 100 (perfect health).
[0144] Constant Score The Constant Score is a scoring system recommended by the European Society for Shoulder and Elbow Surgery and is the most commonly used assessment index in Europe. It is a validated assessment index that includes assessments of pain, function, range of motion, and abduction strength obtained from a patient questionnaire and clinical examination. The Constant Score ranges from 0 to 100 points, with higher scores indicating better outcomes. The MCID for the Constant Score has been reported to be 10.4, and the PASS score is 80.
[0145] MRI scan 3T MRI imaging was performed before treatment and 6 and 12 months after treatment. If a participant had previously had an MRI scan, the pre-treatment MRI was repeated at the investigator's discretion. For example, if the scan had been performed more than 2-3 months before study entry, participants had a pre-treatment MRI, as their clinical condition may have changed during the intervention period.
[0146] Physical Examination A brief physical examination of the affected area was performed to record joint abnormalities, function and to capture any local adverse events following study treatment.
[0147] Simple Shoulder Test The SST was developed in the United States and has been validated in patients with shoulder dysfunction. It measures the functional limitations of the affected shoulder through a 12-item questionnaire completed by the patient. For each item, the patient indicates whether they can or cannot perform the activity, with scores ranging from 0 (worst) to 100 (best). The MCID of the SST has been reported to be 16.7, with a PASS of 70.
[0148] Visual Analogue Scale Pain Assessment (VAS Pain) Visual analog scale (VAS) pain scores range from 0 (no pain) to 10 (worst pain). Participants are asked to rate their pain when it is at its worst, at rest, at night, and when performing tasks on the affected area. An overall pain score for a participant at their visit was calculated by taking the average of all ratings provided by the participant at the visit. The MCID and PASS for VAS pain are reported as 1.4 and 3.0, respectively.
[0149] statistical analysis The statistical principles and methods to be adopted in the analysis of the study data are described in the Statistical Analysis Plan (SAP, version 1, 11 November 2021).
[0150] result Clinical trial period The study began with the randomization of the first participant on July 25, 2017 and ended with the randomization of the last participant on June 17, 2020. The last follow-up visit was completed on August 18, 2021.
[0151] Participant predisposition Thirty-five patients signed informed consent and were formally assessed for eligibility. Three did not have a partial intraparenchymal supraspinatus tendon tear of suitable thickness and were excluded. Two patients assigned to the cell composition group were randomized despite not meeting all eligibility criteria and were subsequently removed from the study before receiving treatment. The final analysis set (FAS) consisted of 11 participants randomized and treated with corticosteroid treatment and 19 participants randomized and treated with the cell composition of the invention. No participants were lost to follow-up in the 12-month post-treatment period, but seven participants in the corticosteroid group chose to withdraw and receive another treatment before the 12-month visit, as permitted by the study protocol.
[0152] Demographics and baseline characteristics The mean age of enrolled participants at the time of study treatment was 50.5 years (SD 8.5, range 30.3-63.4). Ten participants were female and 20 were male. The mean duration of shoulder symptoms was 23.5 months (SD 18.3, range 7-60), and participants had received an average of 4.0 treatments (including corticosteroid injections and physical therapy) prior to study enrollment.
[0153] Efficacy analysis The ASES score includes patient assessment of pain and function and ranges from 0 (worst) to 100 (best) points. The mean baseline ASES score in the cell composition group was 74.2 points (SD 15.2). After treatment, the mean ASES score increased to 82.1 (SD 16.4) at 1 month, 87.1 (SD 13.3) at 3 months, 88.6 (SD 11.4) at 6 months, and 93.3 (SD 7.8) at 12 months. The mean improvements in ASES scores at 6 and 12 months (14.4 and 19.1 points, respectively) were greater than the published MCID for ASES, indicating that, on average, participants experienced meaningful and sustained improvements in pain and function after treatment with the cell composition. Furthermore, at 6 months, 72% of the cell composition group reported ASES scores equal to or better than a "tolerable" symptom state (PASS). This increased to 95% of participants 12 months after treatment.
[0154] The mean ASES score in the corticosteroid group was 62.6 (SD 19.6) at baseline and 63.6 (SD 19.9) at 1 month after treatment. The mean score improved to 74.8 (SD 19.3) at 3 months and decreased slightly at 6 months (mean 74.0, SD 19.8). Seven participants in the corticosteroid group withdrew before 12 months due to worsening symptoms or lack of improvement. Four participants completed 12 months with a mean ASES score of 62.9 (SD 23.6). The mean change in ASES score was 11.4 points at 6 months, which did not meet the threshold for meaningful improvement and there were insufficient data to accurately assess the change from baseline at 12 months. Only 55% of participants achieved a 6-month ASES score that met or exceeded acceptable symptom status.
[0155] Comparisons between groups showed that the mean ASES scores were significantly higher in the cell composition group compared to corticosteroids at all time points after treatment: 1 month (p=0.006), 3 months (p=0.026), 6 months (p=0.012) and 12 months (p=<0.001) (Figure 5).
[0156] Constant Score The Constant Score consists of patient and physician assessments of pain, function, strength, and range of motion. Final scores range from 0 (worst) to 100 (best) points. The mean Constant Score at baseline for the cell composition group was 75.2 (SD 11.6). After treatment, the mean Constant Score increased to 81.8 (SD 11.5) at 1 month, 83.5 (SD 10.3) at 3 months, 84.9 (SD 10.7) at 6 months, and 86.5 (SD 9.5) at 12 months. The mean improvement in Constant Score at 6 months was 9.7 points; slightly below the published MCID for Constant Score. The mean improvement in Constant Score 12 months after treatment was 11.3 points, indicating that, on average, participants experienced meaningful and sustained improvements in pain and function after treatment with the cell composition. Additionally, at 6 months, 73% of the cell composition group achieved a constant score equal to or better than "acceptable" symptom status (PASS), which was maintained at 12 months, with 71% of participants achieving PASS.
[0157] The mean Constant score at baseline in the corticosteroid group was 66.5 (SD 16.3). One month after treatment the mean score was stable at 67.6 (SD 18.3) and then increased slightly to 70.6 (SD 19.6) at 3 months and 71.1 (SD 20.5) at 6 months. Seven participants in the corticosteroid group withdrew before 12 months due to worsening symptoms or lack of improvement. Three participants completed the Constant score at 12 months, averaging 65.4 (SD 23.1). The mean change in Constant score was 4.6 at 6 months, which did not meet the threshold for meaningful improvement and there were insufficient data to accurately assess the change from baseline at 12 months. Only 40% of the corticosteroid group achieved a Constant score at 6 months that met or exceeded acceptable symptom status.
[0158] Comparison between groups showed that the mean constant scores after treatment were significantly higher in the cell composition group compared to the corticosteroid group at 1 month (p=0.020), 6 months (p=0.026), and 12 months (p=0.024).
[0159] Simple Shoulder Test (SST) The SST measures the functional limitations of the affected shoulder based on the patient's assessment of their ability to perform specific tasks with the affected shoulder. Scores range from 0 (worst) to 100 (best) points. The mean baseline SST score for the cell composition treatment group was 67.5 (SD 22.5). After treatment, SST scores improved to 77.8 (SD 19.0) at 1 month, 84.3 (SD 17.8) at 3 months, 88.0 (SD 19.0) at 6 months, and 90.8 (SD 14.1) at 12 months. The mean improvements in SST scores at 6 and 12 months (20.5 and 23.3, respectively) were greater than the published MCID for SST, indicating that, on average, participants experienced meaningful improvements in pain and function after treatment with Ortho-ATI™. Additionally, at 6 months, 89% of the cell composition group reported an SST score equal to or better than "acceptable" symptom status (PASS), which was similar at 12 months post-treatment (84%).
[0160] The mean SST score in the corticosteroid group was 64.4 (SD 22.4) at baseline, worsening to 60.6 (SD 24.5) at 1 month after treatment, then increasing to 69.7 (SD 22.1) at 3 months and 75.0 (SD 26.6) at 6 months. Seven participants in the corticosteroid group withdrew before 12 months due to worsening symptoms or lack of improvement. Four participants completed 12 months with a mean SST score of 77.1 (SD 31.5). The mean change in SST score was 10.6 points at 6 months, which did not meet the threshold for meaningful improvement and there were insufficient data to accurately assess change from baseline at 12 months. At 6 months, 72% of participants had SST scores that met or exceeded acceptable symptom status.
[0161] Comparisons between groups showed that the mean post-treatment SST scores were significantly higher in the cell composition group compared to the corticosteroid group at 3 months (p=0.041) and 12 months (p=0.046).
[0162] Visual Analogue Scale Pain Assessment (VAS Pain) VAS pain ratings range from 0 (no pain) to 10 (worst pain). Participants were asked to rate their pain when it was worst, at rest, when lifting heavy objects, performing repetitive tasks, and at night. An overall pain score was obtained by averaging the scores reported for the individual ratings. The mean VAS pain score at baseline for the cell composition group was 4.8 (SD 1.8). After treatment, the mean VAS pain score improved to 2.8 (SD 1.9) at 1 month, 2.3 (SD 2.0) at 3 months, 2.3 (SD 2.1) at 6 months, and 1.6 (SD 1.3) at 12 months. The mean improvements in VAS pain scores at 6 and 12 months (-2.5 and -3.2, respectively) were greater than the published MCID for VAS pain, indicating that, on average, participants achieved a meaningful reduction in pain after treatment with the cell composition. Additionally, at 6 months, 67% of the cell composition group reported a VAS pain score equal to or better than an "acceptable" symptom state (PASS), which improved to 84% of participants 12 months post-treatment.
[0163] The mean VAS pain score in the corticosteroid group was 5.2 (SD 1.6) at baseline and improved only slightly (mean 5.1; SD 2.0) at 1 month after treatment. The mean score improved to 2.8 (SD 2.0) at 3 months and worsened to 4.2 (SD 1.9) at 6 months after treatment. The mean improvement from baseline in VAS pain score at 6 months (-1.0) was below the threshold for meaningful improvement. Furthermore, only 27% of participants achieved a VAS pain score equal to or better than a published PASS at 6 months. Seven participants in the corticosteroid group withdrew before the 12th month due to worsening symptoms or lack of improvement. Four participants completed the 12th month with a mean VAS pain score of 4.3 (SD 2.0).
[0164] Mean VAS pain scores improved in both treatment groups at 3 months post-treatment. The cell composition group sustained a reduction in pain at 6 months that continued through 12 months post-treatment. In contrast, the reduction in pain in the corticosteroid group was temporary, with VAS pain scores increasing from 3 to 6 months. Comparisons between groups showed that mean VAS pain scores were significantly lower in the cell composition group compared to the corticosteroid group at all time points post-treatment: 1 month (p=0.002), 3 months (p=0.047), 6 months (p=0.010), and 12 months (p=<0.001).
[0165] Quality of Life Assessment (AQoL-6D) AQoL-6D scores range from 0 to 100 (higher scores indicate better health). The mean AQoL-6D score at baseline in the cell composition group was 78.0 (SD 9.3). After treatment, the mean score improved to 83.1 (SD 8.4) at 1 month, 83.5 (SD 8.6) at 3 months, 85.2 (SD 7.1) at 6 months, and 87.5 (SD 6.8) at 12 months.
[0166] The mean AQoL-6D score in the corticosteroid group was 74.6 (SD 8.5) at baseline and scores remained relatively stable at 1 month (72.0; SD 11.9), 3 months (77.2; SD 9.2), and 6 months (79.4; SD 8.7) after treatment. Seven participants in the corticosteroid group withdrew before 12 months due to worsening symptoms or lack of improvement. Four participants completed the 12th month with a mean AQoL-6D score of 76.6 (SD 19.0).
[0167] The two groups showed small improvements in mean AQoL-6D scores after treatment, with the cell composition group improving by 7.2 points at 6 months compared to 4.8 points in the corticosteroid group. The mean improvement in the cell composition group at 12 months was 9.5 points. The cell composition group had a significantly (p=0.010) better mean AQoL-6D score at 1 month compared to the corticosteroid group, but there were no statistically significant differences between the groups at other time points.
[0168] MRI scan All participants underwent a baseline (pre-treatment) MRI evaluation. However, some post-treatment MRI scans were not performed. Six of the eight MRI scans that were not performed were due to COVID-19 regulations. In the corticosteroid group, all participants underwent an MRI six months after treatment. In the cell composition group, 17 of 19 participants underwent an MRI at six months and 16 of 19 participants at 12 months.
[0169] All participants had rotator cuff pathology at baseline, with regional variation in the thickness of intraparenchymal supraspinatus tears and varying degrees of tendonopathy. Clinical evaluation of MRI showed that patients receiving the cell composition showed a trend toward reduced tears and improved tendonopathy, but results were variable. Most participants receiving corticosteroids only had one post-treatment MRI evaluation at 6 months, with many dropping out before the 12-month mark. MRI evaluation showed that many patients receiving corticosteroid injections had persistent tendonopathy, with no definitive change in tendon tear. Semiquantitative evaluation did not match clinical interpretation of post-treatment MRI scans, indicating the lack of a reliable and sensitive method to quantify the effects of treatment using MRI.
[0170] conclusion Statistical analysis showed that the ASES and VAS pain assessment indices were significantly superior in the cell composition group compared to the corticosteroid group at all post-treatment time points. Constant scores were significantly superior in the cell composition group compared to the corticosteroid group at 1, 6, and 12 months, and SST scores were significantly superior in the cell composition group at 3 and 12 months. There were no assessment indices or time points where the corticosteroid group showed significantly better post-treatment results than the cell composition group.
Claims
1. A cell composition comprising isolated tenocytes expressing tenomodulin (TNMD) and scleraxis (Scx).
2. A cell composition comprising isolated tenocytes selected in vitro for the expression of both tenomodulin (TNMD) and scleraxis (Scx).
3. The cell composition of claim 1 , wherein the tenocytes are selectively expanded in culture.
4. The cell composition of claim 3, wherein the tendon cells further express one or more markers selected from the group consisting of Col1A1, TSP-4, TSC, DCN, FN1, BGN and FMOD, or a combination thereof.
5. The cell composition of claim 4 , further comprising a pharma- ceutically acceptable carrier.
6. The cell composition of claim 3, wherein the tendon cells express greater than 100 copies of each marker per μg of cDNA as detected by droplet digital PCR.
7. 1. A method for obtaining a cell composition comprising tendon cells, the composition comprising at least 70% viable tendon cells, the method comprising the steps of obtaining a sample of a mammalian tendon; obtaining a tendon cell suspension from the tendon by performing at least one enzymatic dissociation step; culturing the cell suspension under suitable conditions; selecting tendon cells that express both tenomodulin (TNMD) and scleraxis (Scx); and proliferating the selected tendon cells under suitable conditions to achieve a therapeutic amount.
8. The method of claim 7 , wherein the tendon cells are derived from a tendon sample or a tendon biopsy.
Citation Information
Patent Citations
Bioactive substance composition, serum-free culture medium containing composition and application of serum-free culture medium
CN113692282A
